Drugs / Staloral
Staloral
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 3 | NCT00660452 Comparator | Oct 2007 → Jul 2009 | allergic disease | Stallergenes Greer | Completed | No outcome recorded |
| Phase 4 | NCT01605760 Comparator | Jan 2008 → Jan 2012 | allergic rhinitis | Medical University of Silesia | Completed | No outcome recorded |
| Phase 4 | NCT00250263 Comparator | Nov 2005 → Dec 2008 | allergic rhinitis, asthma | Bayside Health | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Staloral | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00660452 ↗ |
| Known as | Staloral (R) 300 | “Staloral (R) 300 is a sublingual solution of allergen extracts for allergen immunotherapy.” NCT01605760 ↗ |
| Known as | Staloral 300 SR Der p and Der f 50/50% extract | “SLIT was performed with the use of oral Staloral 300 SR Der p and Der f 50/50% extract (Stallergens Greer, London, United Kingdom) or placebo.” PMID 28668244 ↗ Jul 2017 |
| Known as | Staloral 300R | “A total of 51 subjects in the sublingual allergen-specific immunotherapy (SLIT) group (Staloral 300R, Stallergenes, France) and 57 subjects in the placebo group were monitored...” PMID 23331565 ↗ Feb 2013 |
| Modality | Other / unclassified | “Staloral (R) 300 is a sublingual solution of allergen extracts for allergen immunotherapy.” NCT01605760 ↗ |
| Route | Other | “Staloral (R) 300 is a sublingual solution of allergen extracts for allergen immunotherapy.” NCT01605760 ↗ |